◀ Back to IKBKB

CXCL10 — IKBKB

Text-mined interactions from Literome

Yang et al., Clin Cancer Res 2006 (Melanoma) : Inhibition of constitutive IKK activity by BMS-345541 resulted in the reduction of NF-kappaB activity, CXCL1 chemokine secretion by cultured melanoma cells and melanoma cell survival in vitro and in vivo
Edwards et al., Mol Immunol 2007 : Focusing on CXCL8, both rhinovirus infection and dsRNA treatment required IkappaB kinase-beta for induction of CXCL8
Tudhope et al., J Immunol 2007 : The release of CXCL9, CXCL10 , and CXCL11 was inhibited by an IkappaB kinase 2 (IKK2) selective inhibitor 2- [ ( Aminocarbonyl ) amino ] -5- [ 4-fluorophenyl ] -3-thiophenecarboxamide ( TPCA-1 ) ( EC ( 50 ) values were 0.50 +/- 0.03, 0.17 +/- 0.06, and 0.45 +/- 0.10 microM, respectively ( n = 6 ) ) and an IKK1/2 selective inhibitor 2-amino-6- ( 2'cyclopropylemethoxy-6'-hydroxy-phenyl ) -4-piperidin-3-yl-pyridine-3-carbonitrile ( EC ( 50 ) values 0.74 +/- 0.40, 0.27 +/- 0.06, and 0.88 +/- 0.29 microM, respectively ( n = 6 ) ) ... The release of CXCL10 was most sensitive to inhibition by IKK2 and a role for IKK2 in CXCL10 release was confirmed by overexpression of dominant negative adenoviral constructs to IKK2 ( 68.2 +/- 8.3 % n = 5 ), but not of IKK1
Shultz et al., J Interferon Cytokine Res 2007 : Although the IFN-gamma induced expression of the IKKbeta dependent gene ip-10 is sensitive to the superrepressor ( SR ) of IkappaBalpha and requires the p65 subunit of NF-kappaB, IFN-gamma does not activate NF-kappaB